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In the last decade, fertility preservation has risen as a major ﬁeld of interest, creating new interactions between oncologists
and gynecologists. Various options, such as cryopreservation of ovarian tissue, have been developed and are currently routinely
proposedinmanycenters.However,manyoftheoptionsremainexperimentalandshouldbeoﬀeredtopatientsonlyafteradequate
counseling. This paper addresses the eﬃciency and the potential of the diﬀerent fertility preservation approaches.
1.Introduction
Concurrent with the progress over the last few decades in
oncology, the concept of fertility preservation has gained
attention, driving new research endeavors. In the UK, ap-
proximatelyoneoutofevery10cancersoccursinadultsaged
15 to 49 years (Cancer Research UK statistics) and currently,
one out of every 715 adults is a survivor of childhood cancer
[1].
The new approaches to fertility preservation include cry-
opreservation and transplantation of ovarian tissue, follicu-
lar culture, pharmacological protection, or adaptation of an
ovarian stimulation protocol for in vitro fertilization (IVF)
treatment. The choice of an appropriate method is based
mainly on whether a delay in treatment is required, the type
ofthedisease,andthetreatmentthepatienthas.Importantly,
chemotherapy regimens diﬀer widely in their eﬀects on the
gonads. For example, chemotherapy regimens such as vin-
cristine and ﬂuorouracil carry a small risk, whereas other
regimens, such as conditioning of the bone marrow for
transplantation with busulfan, induced premature ovarian
failure in more than 90% of the cases studied, even during
childhood [2, 3].
To address the question of fertility preservation man-
agement, oncology centers must build a close collaboration
with fertility units. In turn, the fertility units themselves
must be able to manage these patients with minimal delay
and oﬀer the optimal option for each case. Although many
centers throughout the world have developed strategies to
propose fertility preservation to their patients, increased
eﬀorts must be made to inform and to oﬀer adequate advice
to the patients regarding their risk of future infertility
and the option of fertility preservation. A recent review
reported that from 34% to 72% of cancer survivors recalled
being counseled by a health provider regarding the impact
of cancer treatments on fertility [4]. In addition to the
fear of losing their fertility, cancer evokes the possibil-
ity of death leading to emotional and psychological dis-
tress. While addressing the issue of fertility preservation,
patients are encouraged to think about their future, which
may help them focus their energies in a positive direc-
tion.2 Obstetrics and Gynecology International
This paper aims to discuss the major concerns regarding
the risk of premature ovarian failure after cancer therapy and
the options for preserving fertility in these patients.
2. Effect of Cancer Treatment on Fertility
Human females are born with a ﬁxed and nonrenewable
number of primordial oocytes that represent the so-called
ovarian reserve. Histological studies and mathematical mod-
els have determined that approximately 1,000,000 oocytes
are present at birth. At menarche, the number of primordial
oocytes has decreased to approximately 180,000 and this
number continues to decline over time with fewer than
1000 oocytes remaining at menopause [5]. Oocyte growth,
diﬀerentiation, and apoptosis are strictly regulated through
autocrine and endocrine loops, with molecular mechanisms
that have recently been elucidated in the Nos3-knockout
mouse model [6, 7]. The pituitary gland produces FSH and
LH in response to LHRH released from the hypothalamus,
whereas estrogen and progesterone produced by the granu-
losa and theca cells, respectively, induce a negative feedback
on LH and FSH production.
Through the partial or total destruction of the ovarian
reserve, cancer treatments may temporarily or deﬁnitively
aﬀect the ovarian function. The most frequent neoplasms
of the reproductive age are breast cancer, malignant lym-
phomas, malignant melanomas, and gynecological cancers,
with an overall incidence of 82.7 cases per 100,000 [8].
Surgery, radiotherapy, and chemotherapy, together with
recentlyisolatedtarget-orientedmolecules,havesigniﬁcantly
improved the prognosis of young cancer patients. Thus,
quality-of-life issues have become a high priority on the
patients’ agenda. Premature menopause and irreversible
sterility are the most dramatic outcomes of ovarian dys-
function; however, infertility and low estrogen levels are
associated with an impaired quality of life and severe
psychological consequences. Thus, infertility and premature
menopause are relevant issues for young women with cancer
and may also inﬂuence their treatment compliance [9].
The mechanism via which chemotherapy impairs ovar-
ian function has not been completely elucidated. It has
been established that drugs have varying eﬀects on ovarian
function, with alkylating agents being the most toxic. Table 1
represents the degree of ovarian toxicity of speciﬁc drugs
used for the treatment of cancer during reproductive ages.
As expected, the total dose is directly correlated to the
ovarian dysfunction [10]. Genetic polymorphism within
the metabolic pathway of cyclophosphamide activation
accounts in part for the diﬀerent toxicities observed in
diﬀerent individuals [11]. The patients’ age is another vari-
able that accounts for the probability of ovarian dysfunction
after chemotherapy. Young patients have a higher absolute
number of primordial oocytes and have a lower rate of
ovarian toxicity after chemotherapy. Nonetheless, young
patients face a sharp reduction of their ovarian reserve
after toxic chemotherapy, and it has been demonstrated
that menopause occurs earlier in cancer survivors who have
received chemotherapy in early adulthood [12, 13]. Table 2
summarizes the rate of chemotherapy-induced amenorrhea,
Table 1: Risk of ovarian toxicity of antineoplastic drugs.
High risk Cyclophosphamide, ifosfamide, busulfan,
mechlorethamine, melphalan
Intermediate risk Doxorubicin, epirubicin, cisplatin,
docetaxel, paclitaxel
Low risk Vincristine, methotrexate, 5-ﬂuorouracil,
trastuzumab
Table 2: Rate of chemotherapy-induced amenorrhea, according to
regimen and age.
Regimen Age <30 yrs Age 30–40 yrs Age >40 yrs
No treatment 1% < 5% 20–25%
Ac x4 — 13% 60%
CMF x6 19% 35% 85%
CAF/CEF x6 30% — 85%
AC x4->Dtax — 55% —
AC: doxorubicin/cyclophosphamide,
CMF: cyclophosphamide/methotrexate/5-ﬂuorouracil,
CAF: cyclophosphamide/doxorubicin/5-ﬂuorouracil,
CEF: cyclophosphamide/epirubicin/5-ﬂuorouracil,
Dtax: docetaxel.
segregated by diﬀerent regimens used in breast cancer, ac-
cording to the patients’ age.
The targets of chemotherapy-induced ovarian toxicity
include primordial oocytes, granulosa cells, and ovarian
stroma. Familiari et al. demonstrated the direct destruction
of primordial oocytes and follicular depletion in ovaries of
young patients treated with regimens containing alkylating
agentsforHodgkin’slymphoma[14].Meirowetal.described
a similar situation in women who were exposed to nonster-
ilizing doses of chemotherapy [15]. Oktem and Oktay used
an ovarian xenograft model to characterize the impact of
chemotherapy on human primordial follicles. They reported
apoptosis of primordial oocytes and growing follicles 12 and
24 hours after cyclophosphamide exposure, with a >90%
reduction of follicle density 48 hours after treatment [16].
Meirow et al. also reported signiﬁcant vascular dam-
age in histological sections of human ovaries exposed to
chemotherapy. They described thickening and hyalinization
of cortical vessels, cortical proliferation of small vessels, and
focal cortical ﬁbrosis with segmental collagen deposition
[15]. These alterations of the normal ovarian anatomy could
be a consequence of drug-induced endothelial damage, fol-
lowed by subsequent neovascularization. Another potential
mechanism of primordial oocyte loss is explained by the
follicular burnout theory. When exposed to chemotherapy,
growing follicles are destroyed, and therefore the amount
of inhibitory paracrine factors, in particular anti-M¨ ullerian
hormone (AMH), is reduced. These changes induce contin-
uous and sustained recruitment of primordial follicles, thus,
“burning out” the ovarian reserve. To date, there is no proof
of this theory in humans, although AMH-knockout mice
have an increased activation of primordial follicles with a
greaternumberofatreticlargefolliclesandareducedovarian
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Littleinformationregardingtheovariantoxicity ofnewly
available drugs for the treatment of young women with
neoplasms is available. For example, trastuzumab is a hu-
manized IgG1 monoclonal antibody that recognizes the
extracellular domain of c-erbB2 receptor. Although c-erbB2
is involved in many diﬀerent cellular processes, no ovar-
ian toxicity has been reported even after prolonged use
[18]. Conversely, monoclonal antibodies targeting VEGF
are able to impair the normal ovulation process in which
angiogenesis plays an important role; however, the data
regarding this aﬀect in humans are not available. Imatinib
is a small molecule that speciﬁcally targets c-Abl and c-
Kit in chronic myeloid leukemia (CML) and gastrointestinal
stromal tumors (GISTs), respectively. This drug has substan-
tially improved the prognosis of patients aﬀected by CML
and GIST and has been proposed as a gonad protector for
patients exposed to chemotherapy. In experimental mod-
els, DNA damage induces TAp63 phosphorylation via c-
Abl, with subsequent cell death. Imatinib inhibits TAp63
phosphorylation in primordial oocytes, thus the oocytes are
protected from apoptosis [19]. Inhibitors of m-TOR (mam-
maliantargetofrapamycin)havebeenusedforthetreatment
of kidney cancer and more recently for the treatment of
neuroendocrine tumors. In men, m-TOR inhibitors induce
severe but reversible azoospermia; however, no data are
available for the eﬀects of m-TOR inhibitors on women [20].
In parallel with the development of a fertility preserva-
tion program, the evaluation of the gonadotoxicity of all
newtherapeuticregimensshouldbesystematicallytakeninto
consideration to adequately inform and manage young pa-
tients who are particularly concerned regarding their future
fertility.
3. Obstetrical Outcome of Cancer Survivors
In addition to diﬃculties with conception due to damage
of the ovaries, long-term female cancer survivors may also
face speciﬁc obstetrical risks. Additionally, concerns have
emerged regarding possible health problems in the oﬀspring.
Adverse events such as miscarriages, preterm delivery,
neonatallow-birthweight,andpostpartumhemorrhagemay
occurmorefrequentlyincancersurvivorsthaninthegeneral
population, depending on the age at treatment and of the
type, dosage, and schedule of the anticancer treatment [21–
23].
While chemotherapy has a major impact on ovarian
function, it rarely directly aﬀects pregnancy outcomes [22].
However, the long-term side eﬀects of some chemotherapy
regimens may increase the risk of adverse obstetrical and
perinatal outcomes. For example, patients treated with
anthracycline or >30Gy of mediastinal radiation may suﬀer
from peripartum cardiomyopathy and should be moni-
tored for cardiac status before pregnancy. However, in a
cohort of 53 childhood cancer survivors, none developed
anthracycline-induced clinical heart failure, thus the risk of
this complication appears to be low [24].
Althoughchemotherapydoesnotaﬀectuterinefunction,
radiotherapy results in diﬀerent degrees of uterine damage
depending on the total dose and the site of irradiation. When
administered in children, pelvic or total body irradiation
(TBI) may result in impaired uterine development. The data
from the Childhood Cancer Survivor Study, based on more
than 2,000 children born from cancer survivors, showed
an overall increased risks for preterm births (21.1% versus
12.6% for the children born from a random sample of the
cancer survivors’ nearest-age full sibling included in the
study as controls; OR = 1.9; 95% CI = 1.4 to 2.4; P<0.0001).
In this study, the risk diﬀered depending on the type and
dose of anticancer treatment (i.e., alkylating, nonalkylating,
or radiotherapy treatment) [21]. The obstetrical risk is
particularly high for patients subjected to pelvic radiation of
>500 cGy; preterm delivery approaches 50% compared with
19.6% for those who did not receive any radiation treatment
(OR 3.5, 95% CI = 1 . 5t o8 ,P<0.003). Additionally, these
babies had lower birth weights (36.2% versus 7,6%, OR =
6.8, 95% CI = 2.1 to 22.2: P<0.0001) and a higher per-
centage were small for gestational age (18,2% versus 7,8%
OR = 4, 95% CI = 2.1 to 22.2, P<0.001). Furthermore,
even patients exposed to lower doses of uterine radiotherapy
have a risk for preterm delivery (from 50cGy) and low
birth weight (from 250cGy). These data were corroborated
by Green (2009) on more than 4,000 pregnancies from the
same database after inclusion of a larger number of cancer
survivors, underlying the lack of evidence of increased risks
of simple malformations, cytogenetic syndromes, or single-
gene defects in the oﬀspring [22].
Additionally, an increased risk of hypertension compli-
cating pregnancy, fetal malposition [25], and post-partum
hemorrhage [23] has been reported in patients receiving
direct uterine radiotherapy, as observed with Wilm’s tumor
patients.
Treatment via estrogen supplements may be helpful, as
it has been demonstrated that in women treated with total
body irradiation, hormone replacement therapy signiﬁcantly
increases uterine volume and endometrial thickness as well
as reestablishing uterine blood ﬂow [26]. Unfortunately,
established hormonal replacement therapy is not as eﬀective
for prepubertal childhood cancer survivors in rescuing their
uterine function.
Thus, when counseling a patient who desires to conceive
afteranticancertherapy,evaluationofthetypeandtotaldose
oftreatmentreceivedandtheageattreatmentshouldbecon-
sidered to estimate the obstetrical risks, with special concern
for patients treated with radiation.
4. Cryopreservation of OvarianTissue
Cryopreservationoftheovariancortexisoneoftheprincipal
techniques utilized for preserving fertility. Indeed, this es-
tablished technique has recently been identiﬁed as highly
promising for this indication.
The ﬁrst studies on cryopreservation of the ovarian cor-
tex were performed on rats in the 1950s [27]. In 1960,
Parrott was the ﬁrst to obtain live young from a mouse
after ovary removal, cryopreservation, and reimplantation.
However, she noted a large decrease in the number of
viable oocytes upon necropsy. This work involved the ﬁrst
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[28]. Paradoxically, despite this positive result, this work also
marked the end of research on this subject for a considerable
period. It was not until 1990 that interest in the freezing of
ovarian tissue reemerged, with the work of Carroll on the
freezing of primary follicles from mice [29]. The protocol
used by Carroll, based on a gradual decrease in temperature,
was similar to the protocols used for the freezing of embryos,
with dimethylsulfoxide used as a cryoprotective agent. In
mice, this technique allowed the survival of oocytes (80%)
and of the surrounding somatic cells (65%). Oﬀspring
were obtained after freezing isolated follicles, thawing, and
transplantation to the ovarian bursa of host animals [30].
The same freezing protocol has been used for fragments
of ovary from ewes, leading to the birth of a lamb after an
autologous transplantation [31].
T h eﬁ r s tw o r ko nc ry o p r e s e rv a t i o no ft h eh u m a no v a ri a n
cortex was published in 1996. The various freezing protocols
tested were compared with that described by Carroll et
al. [29]. Hovatta provided the ﬁrst demonstration that the
freezing of human ovarian cortex was feasible [32]. After
thawing and histological analysis, freezing and thawing were
foundtohavehadnoeﬀectonthenumberoffollicles,follicle
diameter, or oocyte diameter, regardless of the cryopro-
tectant agent used (DMSO- or PROH-sucrose). In the same
year, Newton et al. compared the eﬀects of four cryopro-
tectant agents (DMSO, ethylene glycol (EG), PROH, and
glycerol) on the survival of human ovarian tissue after
freezing. Follicular survival rates were the highest with EG
(84%) and the lowest with glycerol (10%), with those for
DMSO (74%) and for PROH (44%) falling between these
values[33].Thesestudiesalsoshowedthatfreezingprotocols
similar to those used to obtain a live lamb from an ewe—a
large mammal in which ovary organization resembles that
in women—through freezing/thawing and the autologous
transplantation of ovarian tissues were transposable to hu-
mans.
Thus, in the mid-1990s the idea ﬁrst emerged from pre-
serving the fertility of patients or from creating oocyte banks
through freezing ovarian tissue to treat infertility [34]. It
became clear that cryopreservation of the ovarian cortex
was potentially useful for patients having to undergo highly
gonadotoxic treatments because it would be possible to
preserve a large number of primordial follicles. Of note, the
ﬁrst reported case of ovarian cortex cryopreservation in a
patient was published in 1996 [35].
Cryopreservation of the ovarian cortex has since become
an integral part of fertility preservation, and results from
several cohort studies have been published [36–39].
Indications. Ovarian cryopreservation involves the removal
of all or part of one of the two ovaries and thus, the excision
of a substantial proportion of the follicular capital of the
patient. Therefore, cryopreservation should only be oﬀered
to patients undergoing highly gonadotoxic treatments. The
various treatments have been classiﬁed according to their
toxicity to the ovaries [40, 41]. The age of the patient must
also be taken into account, as the impact on the ovarian
reserve is lower in younger patients. It would therefore be
justiﬁed to oﬀer ovarian tissue cryopreservation in three
situations in which it is almost certain that ovarian function
will be altered at the end of treatment: chemotherapy with
high doses of alkylating agents (such as busulfan or cyclo-
phosphamide); total body irradiation or abdominal radia-
tion; bilateral ovariectomy or unilateral ovariectomy of a
single-remaining ovary. Ovary cryopreservation may also be
oﬀered in cases of disease associated with premature ovary
failure, such as Turner syndrome [42, 43].
This technique has many advantages. In addition to
allowing the preservation of a large number of immature
oocytes within primordial follicles, this technique does not
require ovarian stimulation and can be organized very
rapidly without the need to defer treatment of the disease.
It is available to patients regardless of their marital status
and is the only possible technique for fertility preservation
in prepubescent girls [2, 36]. By contrast, an upper age limit
of 35 to 37 years is recommended for the cryopreservation
of ovarian tissue [44]. The risks of ovary tissue harvesting
appear to be small: only a single patient was reported to
have required surgical revision among the 500 cases of ovary
cryopreservation described by the FertiPROTEKT network
[44].
In practice, ovarian tissue is usually obtained via laparo-
scopy. However, it may be collected via laparotomy, particu-
larly from patients treated for neuroblastoma. In these cases,
the ovary can be harvested during resection of the residual
tumor,aprocedurescheduledpriortohigh-dosechemother-
apy and the autologous transplantation of hematopoietic
stem cells. The quantity of tissue removed is variable; part
or all of an ovary may be removed or ovarian tissue may be
excised via biopsy [45].
The operating theater is rarely adjacent to the laboratory
in which the ovarian tissue is frozen and stored. Therefore,
the ovary must be transported in optimal conditions to the
site of freezing immediately after its removal. Most authors
recommend that transport times should be kept as short
as possible. However, a series of ﬁve pregnancies following
the autologous transplantation of frozen and thawed ovarian
tissue has been reported, including two cases in which the
fragments of ovarian tissue were frozen only after transport
periods of four to ﬁve hours [46].
The penetration of cryoprotectant agents into the tissues
is limited. Isolation of the ovarian cortex through the
removal of the medulla is therefore important, to reduce
the thickness of the ovarian tissue, thereby optimizing
follicular survival [47]. After a period of equilibration with
a cryoprotective agent, the ovarian fragments are frozen in a
slow-freezing protocol. Indeed, all the pregnancies achieved
to date have involved the slow freezing of ovarian tissue.
Two major developments are currently the subjects of a
heated debate: the vitriﬁcation of ovarian tissue fragments
[48, 49] and the freezing of the entire ovary [50, 51]. It
has recently been shown that the ultrastructure of human
follicles is conserved during vitriﬁcation in a closed system
based on cryotubes [52]. Freezing of the whole ovary has
been proposed as a solution for limiting the phenomenon
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fragment revascularization following autologous transplan-
tation.Mostrelevantstudieshavebeenperformedintheewe,
despite the ovary being smaller in lambs and diﬀerences in
the anatomy of the vascular pedicle. The technique involves
the perfusion of ovarian vessels with freezing solution, then
placing the ovary in a tube containing a similar solution.
The eﬃcacy of this technique was demonstrated for the ﬁrst
time in 2004. The transplantation of an entire ovary that
had been frozen in DMSO allowed the revascularization of
the ovary using microsurgical reanastomosis in ﬁve of eight
ewes (62.5%). Normal estrus cycles were reestablished in
three of the ewes, as demonstrated via progesterone levels
[51]. Oocytes have been obtained from frozen whole ovaries
in ewes [53], although this procedure is ineﬃcient (after
autologous transplantation only, 25% of the ovaries were
functional), and a single birth has been achieved using this
method [54].
Only few studies have reported the freezing of an entire
human ovary. No signiﬁcant diﬀerence in follicular viability
between whole frozen ovaries and frozen ovary fragments
was observed [50]. These results have since been conﬁrmed
by Martinez-Madrid et al. [55].
Finally, ovary harvesting could also make it possible to
developadditionaltechniquesforpreservingfertility.Indeed,
the freezing of ovarian tissue may be combined with the
removal, via puncture, of small antrum follicles that may be
present in the ovary at the time of harvesting. This makes
it possible (1) to freeze ovary tissue and isolated immature
oocytes [42]; (2) to freeze isolated oocytes present in the
dissectionmediumwhenovaryfragmentsaregenerated[56];
or (3) to freeze pre-antral follicles present in the medulla,
where they may be highly abundant [57].
5.Transplantationof OvarianTissue
At present, ovarian tissue grafting is the only option for
potentially restoring ovarian function and fertility after cry-
opreservation and storage of ovarian tissue. Diﬀerent groups
throughouttheworldhavepublishedtheresultsofsuccessful
transplantation procedures leading to the reactivation of the
ovarian endocrine activity and ovulation [58].
Despitethesepromisingresults,thetechniqueshouldnot
beconsideredaroutineclinicalprocedure,astherehavebeen
fewer than 20 babies born through this method in the last
decade [59]. It is diﬃcult to perform statistical analysis on
the eﬃciency of the procedure because a limited number of
patients underwent ovarian autotransplantation compared
with the number of patients whocryopreserved their ovarian
tissue. A pregnancy rate per transplantation ranging from
20% to 30% appearsto be realistic, although the delivery rate
may be lower [59–61].
Diﬀerent protocols have been applied to perform the
grafting, with a wide variability concerning the site of the
transplantation [62]. The ovarian tissue is able to restart
folliculogenesis up to ovulation when grafted either to an
orthotopicsite(ovarianfossa,remainingovary)ortoaheter-
otopic site (e.g., peritoneal abdominal wall, uterine serosa,
subcutaneously on the abdominal wall or in the forearm).
Despite the fact that ovulation, egg retrieval, in vitro
fertilization, and early-stage embryo development can occur
after heterotopic transplantation and lead to biochemical
pregnancy, ongoing pregnancy and delivery have been
obtained only after orthotopic graft at the ovarian site [63–
66]. After the transplant, variability has been observed in the
time needed to restore ovarian activity and in the lifespan
of the graft. Follicular development generally occurs in 4 to
5 months because at least 120 days are necessary to initiate
follicular growth, but it has been observed to occur in a
wide window between 8 and 26 weeks [60]. The graft can
be functional from 3 to 4 months up to more than ﬁve years
(personal data). Several factors may explain these important
clinical variations, such as the original follicle density in
the ovarian tissue, the amount of tissue transplanted, the
age of the patient at the time of cryopreservation, the
freezing/thawing technique, the ischemic injury at the time
ofthegraftbeforeneoangiogenesisoccurs,andthehormonal
environment [62].
Based on these observations, various strategies have been
suggested to optimize the function of the transplant, such as
graft of isolated follicles, extremely thin ovarian fragments
[67, 68], or pretreatment of the host and graft with hor-
mones, vitamins, and growth factors [69, 70]. Moreover,
orthotopic and heterotopic transplant of the whole ovary
with vascular anastomosis of the pedicle vessels was per-
formed successfully in humans with fresh organs in cases
of pelvic irradiation or allotransplantation of monozygotic
twins discordant for ovarian failure [71–74], but further
investigations on cryopreservation of the entire ovary are
needed in both humans and animal models.
A major concern when transplanting ovarian tissue to
a patient treated for oncological disease is the possible risk
of reintroduction of cancer cells within the graft. This
risk is diﬀerent depending on the type and stage of the
original cancer. Diﬀerent authors have classiﬁed pathology
as low, intermediate, and high risks of recurrence in cases of
transplant to drive their decision; for example considering
Hodgkin’s lymphoma as low risk, breast cancer as intermedi-
ate risk, and leukemia as high risk [75].
As transplantation is the only option available at present
to restore fertility using cryopreserved ovarian tissue, each
patient should be clearly informed regarding the safety issue
and the limitations of ovarian tissue transplantation proce-
dures at the time of the fertility preservation counseling.
6. InVitroMaturationand
Oocyte Vitriﬁcation
Vitriﬁcation of oocyte and embryos is a well-established pro-
cedure and is currently performed in many IVF laboratories
withahighsuccessrate.Thisprocedureshouldbeconsidered
as a ﬁrst option for fertility preservation, before gonadotoxic
treatment, when feasible. However, stimulation protocols for
oocyte or embryo freezing in cancer patients present two
main safety issues.
The ﬁrst concern is the exposure to superphysiological
estrogen levels, which may be 10–20 times more than those
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a temporary increase in estradiol levels on the risk of the
recurrence of cancer is uncertain, it remains a concern in
cases of hormone-dependent tumors [78, 79].
The second concern is that the duration of the treatment
may delay the start of the chemotherapy. Due to the risks
inherent in the malignant disease, fertility preservation
cannot postpone the treatment course.
Recently, emergency procedure of random start-con-
trolled ovarian stimulation in the late follicular phase or in
thelutealphasehavebeenreportedwithsuccess,signiﬁcantly
shorteningthetimerequiredtoundergoneoocyteorembryo
cryopreservation before chemotherapy [80]. Furthermore,
this treatment can be associated with letrozole adminis-
tration to reduce the eﬀect of temporary increase of the
oestradiol level in the case of hormone sensitive tumor [81].
Another strategy to avoid those safety issues is the use of
in vitro maturation (IVM) of oocytes and vitriﬁcation.
6.1. Cryopreservation of Oocytes. During cryopreservation
procedure, three major mechanisms may potentially damage
the cell, including chilling injury (+15 to −5◦C), ice crystal
formation (−5t o−80◦C), and fracture damage occurring
fromsolidiﬁedﬂuidwithinthecell(−50to −150◦C).During
warming stages, the cell is subjected to the same injuries
in reverse order [82]. Two techniques are used in assisted
reproduction laboratories for cryofreezing; controlled slow
freezing (SF) and, more recently, an ultrarapid cooling
method also known as vitriﬁcation. Both involve the use of
cryoprotectants to minimize ice-crystal formation [82].
Speciﬁc characteristics unique to oocytes make them
more susceptible to injuries induced by slow freezing; these
characteristics include their size, shape, and water content.
These injuries result in spindle and cytoskeleton damage,
crystal formation, and zonal hardening. Those changes ex-
plain the lower fertilization and implantation rates observed
with frozen-thawed oocytes [83].
Vitriﬁcationwasintroducedasameanstoprotectagainst
the ice-crystal formation that has been observed with slow
cooling. The tissue is submerged directly into liquid nitrogen
after being treated with high concentration of cryoprotec-
tant, and freezing occurs without allowing crystal formation
[84]. Recently, the use of low concentrations of the cry-
oprotectants oﬀsets their observed toxicity towards oocytes
[85]. Furthermore, ICSI and improvements in culture media
have helped overcome other side eﬀects of vitriﬁcation, such
as zonal cracks and hardening. Thus, a steady increase in
oocyte survival, fertilization, and pregnancy rates has been
observed.Pregnancyratesafteroocytevitriﬁcationhavebeen
reported in the 10–30% range [86, 87]. In a meta-analysis by
Cobo and Diaz in 2011, vitriﬁcation methods demonstrated
a higher fertilization rate, cleavage rate, and optimal quality
rate of the embryo compared with slow freezing [88]. At
the MUHC Reproductive Center, we reported a mean oocyte
survival rate of 81% after thawing, a 76% fertilization rate
per oocyte, a clinical-pregnancy rate per cycle of 45%, a
live-birth rate of 40%, and the birth of 22 healthy babies
[89]. By 2009, nearly 1,000 live births were reported from
oocyte cryopreservation with an incidence of congenital
abnormalities in these children of 1.3%, similar to that
observed in the general ART population [90].
6.2. In Vitro Maturation of Oocytes. Due to a concernregard-
ing hormonal sensitivity, gonadotropin treatment could be
avoided via the collection of immature oocytes in unstimu-
lated cycles for fertility preservation [91, 92]. This procedure
results in the successful preservation of fertility with no delay
in the administration of chemotherapy, no surgery, and a
lack of the necessity of gonadotropin stimulation.
T h eo o c y t ec o l l e c t i o ni sp e r f o r m e d3 8h o u r sa f t e r
hCG priming, ideally when the largest follicle has reached
10–12mm [93, 94]. If there is no suﬃcient time prior
to chemotherapy for conventional follicular phase oocyte
retrieval in a stimulated or unstimulated cycle, retrieval
in the luteal phase could be considered [95, 96]. After
collection, the oocyte maturation status is assessed; imma-
ture oocytes are cultured in IVM medium and periodically
assessed for maturation status as previously described [93].
When the female patient does not have a stable partner and
does not wish to use donor sperm to create embryos, she
can opt for oocyte cryopreservation. However, vitriﬁcation
of oocytes matured in vitro remains in the experimental
phase, as only a 20% live-birth rate per cycle from vitriﬁed of
IVM oocytes has been reported [89] due to the signiﬁcantly
lower survival and fertilization rates compared with oocytes
collected following ovarian stimulation [94]. Notably, these
studies demonstrated that vitriﬁcation of in vitro matured
oocytes collected from unstimulated cycles followed by later
thawing and fertilization can result in successful pregnancies
and live births. In 2009, we published a report of the ﬁrst 4
live births achieved after vitriﬁcation and thawing of in vitro
matured oocytes [86].
Although it was expected that smaller immature oocytes
would have an increased survival rate when undergoing the
cryopreservation procedure, the potential of oocyte matu-
ration is reduced by the vitriﬁcation at the GV stage [97].
Therefore, immature oocytes are currently matured in vitro
prior to vitriﬁcation.
After thawing, ICSI was routinely performed 2–4 hours
after polar body extrusion due to a theoretical risk of zonal
hardening during the in vitro culture period [98].
The main disadvantage of IVM concerns lower preg-
nancy rates when compared with conventional IVF due
to lower implantation rates [99]. This has been overcome
through transferring one embryo more than in IVF, which
allows comparable pregnancy rates to those of IVF to be
attained (McGill, unpublished data).
Safety issues of IVM have been evaluated in several
studies. Buckett et al. compared congenital anomalies in
432 patients undergoing IVF (217), IVM (55), and ICSI
(160) with non-ART-conceived children [100]. There was no
increase in congenital anomalies after IVM when compared
with spontaneously conceived children. A recent retro-
spective study also observed no increase in chromosomal
abnormalities in 6 children born after IVM when compared
with 30 children born after classical IVF [101]. Those initial
reports are encouraging, though few in numbers. Thus, the
safety of IVM must be conﬁrmed with larger-scale studies.Obstetrics and Gynecology International 7
To date, the MUHC Reproductive Center has provided
fertility preservation to 183 patients with breast, hematolog-
ical, brain, soft-tissue, colorectal, and gynecological cancers.
Of these, 128 patients underwent oocyte retrieval without
ovarian stimulation followed by IVM.
7. Pharmacological Protection
Pharmacological protection of the gonads during chemo-
therapy constitutes an attractive option to preserve fertility.
It may allow the restoration of normal ovarian function and
natural fertility after treatment and may therefore save the
patients from adverse events related to premature ovarian
failure.
The gonadotropin-releasing hormone agonist (GnRHa)
is a decapeptide derived from the native hormone; however,
this synthetic hormone binds to speciﬁc pituitary receptors
with a higher aﬃnity. The sustained-release of GnRHa
initially stimulates the release of gonadotropins, inducing
a brief ovarian hyperstimulation, commonly known as the
ﬂare-up response. After 10–15 days, pituitary GnRH recep-
tors are downregulated and the inhibitory eﬀect of the
synthetic hormone on ovarian function is observed. During
treatment, the hormonal proﬁle is characterized by low
gonadotropin and estradiol levels. This inhibitory eﬀect may
protect the ovarian function during chemotherapy through
diﬀerent mechanisms, such as maintaining the follicles
at the primordial/primary stages, decreasing sensitivity to
gonadotoxic treatment, or through the reduction of the
blood supply.
The eﬀectiveness of the treatment was ﬁrst reported in
rats and monkeys in the 1980s. Administration of GnRha
during chemotherapy has proven to reduce follicular deple-
tion in rats treated with cyclophosphamide [102, 103].
Experiments using monkeys demonstrated that 65% of
the primordial follicular pool is destroyed after cyclophos-
phamide treatment compared with 29% with Gn-Rha
cotreatment [104]. Although this protective eﬀect in animals
has been supported by another study [105], this eﬀect has
been reported as limited or dose dependent [106] and not
suﬃcient to protect fecundity by others [107]. The eﬃciency
of GnRh antagonist in inducing an immediate ovarian
suppression through competitively blocking GnRh receptor
in the pituitary has also been investigated with divergent
conclusions according to the published reports [108–110].
In humans, the eﬃciency of GnRha in preventing
premature ovarian failure was controversial for years and
is still debated. Nonrandomized studies suggested a reduc-
tion of premature ovarian failure rate when GnRha was
administeredconcomitantlytothechemotherapy[111,112].
However, the methodology of these studies was criticized,
thus calling the results into question [113, 114]. Waxman
et al. ﬁrst reported the results of a prospective, randomized
study on a cohort of 18 patients and failed to demonstrate
any signiﬁcant protective eﬀect of GnRHa treatment after
two years of followup [115]. In a cohort of 80 randomized
patients treated for breast cancer, Badawy et al. reported
a reduction in premature ovarian failure rate with GnRha
[116].However,meanFSHvalueswerelowerthan20IU/Lin
both groups and FSH value deﬁning premature ovarian fail-
ure was not indicated. Furthermore, the data were collected
after less than 1 year of followup.
Recently,GnRhacotreatmentfailedtopreventpremature
ovarian failure in a small cohort of patients with Hodgkin’s
lymphoma treated with a regimen of escalated BEACOPP
(bleomycin, etoposide, adriamycin, cyclophosphamide, vin-
cristine, procarbazine, and prednisolone) [117]. The ZORO
study reported no signiﬁcant diﬀerences in the restoration
of the spontaneous cycle and hormonal proﬁle after GnRha
co-treatment compared with control in patients up to 45
yearsofagetreatedforbreastcancer[118].However,possible
biases were highlighted regarding the results of this study
[119]. A recent meta-analysis suggests a potential beneﬁt
of GnRha treatment during chemotherapy on spontaneous
resumption of menses and ovulation, but not on pregnancy
rate. The authors of this meta-analysis also moderated their
conclusion by listing the risk of bias in the published trials
assessing this issue [120]. The largest randomized study of
281 early breast cancer patients was recently published by del
Mastro et al. (2011), showing a reduction in the occurrence
of early menopause in the group of patients with breast
cancer treated with GnRha during chemotherapy after 1 year
of follow-up [121]. In contrast, the eﬃciency of triptorelin
to prevent premature ovarian failure after 1 year of follow-
up was not observed in a cohort of 80 randomized young
patients treated for lymphoma [122].
Thus,despitethepotentialeﬃciencyofGnRhatoprevent
premature ovarian failure suggested by some of the studies,
the results must be conﬁrmed in the future. Additionally,
the eﬀect of GnRha on the fertility of the patients must be
further investigated. GnRha treatment may also have addi-
tional advantages that should be taken into consideration,
such as reducing the risk of thrombocytopenia-associated
menorrhagia during chemotherapy [123]. GnRha treatment
during chemotherapy is actually proposed as an option to
preserve fertility in many centers worldwide. However, this
option should be oﬀered as part of a clinical trial after careful
counseling regarding the other existing available options to
preserve fertility.
Globally, a new concept of “fertoprotective adjuvant
therapy” has arisen. This concept supports that molecules
could be developed to directly prevent DNA damage caused
by chemotherapeutic agents on gonads without interfering
with their eﬃciency. A more thorough understanding of
the mechanism of oocyte damage and DNA repair during
chemotherapy is essential to address this question. In mice,
oocytes lacking the gene for acid sphingomyelinase or wild-
type oocytes treated with sphingosine-1 phosphate-resisted
apoptosis induced through anticancer therapy [124]. Sphin-
gosine 1-phosphate also led to the preservation of fertility
in irradiated female mice without propagating genomic
damage to the oﬀspring [125]. Other proteins involved in
apoptosis, such as Bax and Rad51, play a critical role in
oocyte death after doxorubicin treatment or during age-
related physiological oocyte depletion [126]. Experiments
in mice show that AS101, a nontoxic immunomodulator,
can speciﬁcally protect against cyclophosphamide-induced
damage in the testis [127].8 Obstetrics and Gynecology International
Recently,anewpotential protectivedrug,imatinib(trade
name Gleevec), was also investigated in cisplatin-treated
mice [19]. These results oﬀer a promising approach for the
use of chemotherapy without harming the resting germ cell
[128].
This important ongoing experimental research may con-
tribute to the development of new protective candidate ther-
apies targeting individualized chemotherapeutic agents.
8. Conclusion
The option to preserve fertility must be chosen after mul-
tidisciplinary counseling for each patient. Each option pre-
sents advantages or contraindications that must be taken
into consideration; however, none of them guarantees the
success of the procedure. Thus, the combination of diﬀerent
techniques may oﬀer the best chance to restore the fertility of
the patients in the future.
The combination of ovarian tissue cryobanking and
immature oocyte collection from the tissue followed by
IVM and vitriﬁcation of the matured oocytes (or embryos)
represents a promising approach for fertility preservation.
Furthermore, these immature oocytes can be collected at
any time of the cycle. Recently, preantral follicle isolation
from the medulla during ovarian tissue cryopreservation was
alsoreported,oﬀeringadditionalmaterialsforstorage.When
feasible, a classical IVF protocol with prior gonadotropin
stimulation should be proposed, as it remains the only estab-
lished procedure for storing gametes.
Finally, reducing the gonadotoxicity of the treatment by
adaptingthechemotherapyregimen,protectingovariesfrom
irradiation, or using pharmacological protective therapy can
also be proposed associated with a cryopreservation proce-
dure.
9. Disclosure
The co-authors are listed alphabetically and equally contrib-
uted to the paper.
References
[1] M. F. H. Brougham and W. H. B. Wallace, “Subfertility in
children and young people treated for solid and haematolog-
ical malignancies,” British Journal of Haematology, vol. 131,
no. 2, pp. 143–155, 2005.
[2] P.Jadoul,M.M.Dolmans,andJ.Donnez,“Fertilitypreserva-
tion in girls during childhood: is it feasible, eﬃcient and safe
and to whom should it be proposed?” Human Reproduction
Update, vol. 16, no. 6, Article ID dmq010, pp. 617–630, 2010.
[3] D. Meirow, “Reproduction post-chemotherapy in young
cancer patients,” Molecular and Cellular Endocrinology, vol.
169, no. 1-2, pp. 123–131, 2000.
[4] S. Tschudin and J. Bitzer, “Psychological aspects of fertility
preservation in men and women aﬀected by cancer andother
life-threatening diseases,” Human Reproduction Update, vol.
15, no. 5, pp. 587–597, 2009.
[5] W. H. Wallace and T. W. Kelsey, “Human ovarian reserve
from conception to the menopause,” PLoS ONE, vol. 5, no.
1, Article ID e8772, 2010.
[ 6 ]R .L .R o b k e r ,D .L .R u s s e l l ,S .Y o s h i o k ae ta l . ,“ O v u l a t i o n :a
multi-gene, multi-step process,” Steroids, vol. 65, no. 10-11,
pp. 559–570, 2000.
[7] P. Pallares and A. Gonzalez-Bulnes, “The eﬀect of embryo
and maternal genotypes on proliﬁcacy, intrauterine growth
retardation and postnatal development of Nos3-knockout
mice,” Reproductive Biology, vol. 10, no. 3, pp. 241–248, 2010.
[8] W. Murk and E. Seli, “Fertility preservation as a public health
issue: an epidemiological perspective,” Current Opinion in
Obstetrics and Gynecology, vol. 23, no. 3, pp. 143–150, 2011.
[9] A. H. Partridge, S. Gelber, J. Peppercorn et al., “Web-based
survey of fertility issues in young women with breast cancer,”
Journal of Clinical Oncology, vol. 22, no. 20, pp. 4174–4183,
2004.
[10] H. Koyama, T. Wada, Y. Nishizawa, T. Iwanaga, and Y.
Aoki, “Cyclophosphamide induced ovarian failure and its
therapeutic signiﬁcance in patients with breast cancer,”
Cancer, vol. 39, no. 4, pp. 1403–1409, 1977.
[ 1 1 ]V .S t e a r n s ,B .S c h n e i d e r ,N .L .H e n r y ,D .F .H a y e s ,a n dD .A .
Flockhart, “Breast cancer treatment and ovarian failure: risk
factors and emerging genetic determinants,” Nature Reviews
Cancer, vol. 6, no. 11, pp. 886–893, 2006.
[12] A. H. Partridge, K. J. Ruddy, S. Gelber et al., “Ovarian reserve
in women who remain premenopausal after chemotherapy
for early stage breast cancer,” Fertility and Sterility, vol. 94,
no. 2, pp. 638–644, 2010.
[13] A. Partridge, S. Gelber, R. D. Gelber, M. Castiglione-Gertsch,
A. Goldhirsch, and E. Winer, “Age of menopause among
women who remain premenopausal following treatment for
early breast cancer: long-term results from International
Breast Cancer Study Group Trials V and VI,” European
Journal of Cancer, vol. 43, no. 11, pp. 1646–1653, 2007.
[14] G. Familiari, A. Caggiati, S. A. Nottola, M. Ermimi, M. R.
di Benedetto, and P. M. Motta, “Ultrastructure of human
ovarian primordial follicles after combination chemotherapy
for Hodgkin’s disease,” Human Reproduction, vol. 8, no. 12,
pp. 2080–2087, 1993.
[ 1 5 ]D .M e i r o w ,J .D o r ,B .K a u f m a ne ta l . ,“ C o r t i c a lﬁ b r o s i s
and blood-vessels damage in human ovaries exposed to
chemotherapy. Potential mechanisms of ovarian injury,”
Human Reproduction, vol. 22, no. 6, pp. 1626–1633, 2007.
[16] O.OktemandK.Oktay,“Anovelovarianxenograftingmodel
tocharacterizetheimpactofchemotherapyagentsonhuman
primordial follicle reserve,” Cancer Research, vol. 67, no. 21,
pp. 10159–10162, 2007.
[17] A. L. L. Durlinger, P. Kramer, B. Karels et al., “Control of
primordial follicle recruitment by anti-mullerian hormone
in the mouse ovary,” Endocrinology, vol. 140, no. 12, pp.
5789–5796, 1999.
[18] H. A. Azim Jr., F. A. Peccatori, S. J. Liptrott, C. Catania, and
A. Goldhirsch, “Breast cancer and pregnancy: how safe is
trastuzumab?” Nature Reviews Clinical Oncology, vol. 6, no.
6, pp. 367–370, 2009.
[19] S. Gonﬂoni, L. di Tella, S. Caldarola et al., “Inhibition of
the c-Abl-TAp63 pathway protects mouse oocytes from
chemotherapy-induced death,” Nature Medicine, vol. 15, no.
10, pp. 1179–1185, 2009.
[ 2 0 ]E .H u y g h e ,A .Z a i r i ,J .N o h r a ,N .K a m a r ,P .P l a n t e ,a n dL .
Rostaing, “Gonadal impact of target of rapamycin inhibitors
(sirolimus and everolimus) in male patients: an overview,”
Transplant International, vol. 20, no. 4, pp. 305–311, 2007.
[21] L. B. Signorello, S. S. Cohen, C. Bosetti et al., “Female
survivors of childhood cancer: preterm birth and low birthObstetrics and Gynecology International 9
weight among their children,” Journal of the National Cancer
Institute, vol. 98, no. 20, pp. 1453–1461, 2006.
[22] D. M. Green, C. A. Sklar, J. D. Boice Jr. et al., “Ovarian failure
and reproductive outcomes after childhood cancer treat-
ment: results from the childhood cancer survivor study,”
Journal of Clinical Oncology, vol. 27, no. 14, pp. 2374–2381,
2009.
[ 2 3 ]S .L .F o n g ,M .M .v a nd e nH e u v e l - E i b r i n k ,M .J .C .
Eijkemans, I. Schipper, C. W. P. M. Hukkelhoven, and J. S.
E. Laven, “Pregnancy outcome in female childhood cancer
survivors,” Human Reproduction, vol. 25, no. 5, pp. 1206–
1212, 2010.
[24] E. C. van Dalen, H. J. H. van der Pal, C. van den Bos, W. E.
M. Kok, H. N. Caron, and L. C. M. Kremer, “Clinical heart
failure during pregnancy and delivery in a cohort of female
childhood cancer survivors treated with anthracyclines,”
European Journal of Cancer, vol. 42, no. 15, pp. 2549–2553,
2006.
[25] D. M. Green, J. M. Lange, E. M. Peabody et al., “Pregnancy
outcome after treatment for Wilms tumor: a report from the
national Wilms tumor long-term follow-up study,” Journal of
Clinical Oncology, vol. 28, no. 17, pp. 2824–2830, 2010.
[ 2 6 ]L .E .B a t h ,H .O .D .C r i t c h l e y ,S .E .C h a m b e r s ,R .A .
A n d e r s o n ,C .J .H .K e l n a r ,a n dW .H .B .W a l l a c e ,“ O v a r i a n
and uterine characteristics after total body irradiation in
childhood and adolescence: response to sex steroid replace-
ment,” British Journal of Obstetrics and Gynaecology, vol. 106,
no. 12, pp. 1265–1272, 1999.
[27] A. S. Parkes and A. U. Smith, “Regeneration of rat ovarian
tissue grafted after exposure to low temperatures,” Proceed-
ings of the Royal Society of London B, vol. 140, no. 901, pp.
455–470, 1953.
[28] D. M. Parrott, “The fertility of mice with orthotopic ovarian
grafts derived from frozen tissue,” Journal of Reproduction
and Fertility, vol. 1, pp. 230–241, 1960.
[29] J. Carroll, H. Depypere, and C. D. Matthews, “Freeze-thaw-
induced changes of the zona pellucida explains decreased
rates of fertilization in frozen-thawed mouse oocytes,” Jour-
nal of Reproduction and Fertility, vol. 90, no. 2, pp. 547–553,
1990.
[30] J. Carroll and R. G. Gosden, “Transplantation of frozen-
thawed mouse primordial follicles,” Human Reproduction,
vol. 8, no. 8, pp. 1163–1167, 1993.
[31] R.G.Gosden,D. T.Baird,J.C.Wade, andR.Webb, “Restora-
tion of fertility to oophorectomized sheep by ovarian auto-
grafts stored at -196◦C,” Human Reproduction,v o l .9 ,n o .4 ,
pp. 597–603, 1994.
[32] O. Hovatta, R. Silye, T. Krausz et al., “Cryopreservation
of human ovarian tissue using dimethylsulphoxide and
propanediol-sucrose as cryoprotectants,” Human Reproduc-
tion, vol. 11, no. 6, pp. 1268–1272, 1996.
[33] H. Newton, Y. Aubard, A. Rutherford, V. Sharma, and R.
Gosden, “Low temperature storage and grafting of human
ovarian tissue,” Human Reproduction,v o l .1 1 ,n o .7 ,p p .
1487–1491, 1996.
[34] J. Carroll, “Development of oocyte banks and systems for
the in-vitro development of oocytes: future directions for
the treatment of infertility,” Human Reproduction, vol. 11,
supplement 1, pp. 159–168, 1996.
[35] G. Bahadur and S. J. Steele, “Ovarian tissue cryopreservation
for patients,” Human Reproduction, vol. 11, no. 10, pp. 2215–
2216, 1996.
[36] C. Poirot, M. C. Vacher-Lavenu, P. Helardot, J. Guibert, L.
Brugi` eres, and P. Jouannet, “Human ovarian tissue cryop-
reservation: indications and feasibility,” Human Reproduc-
tion, vol. 17, no. 6, pp. 1447–1452, 2002.
[37] K. T. Schmidt, E. C. Larsen, C. Y. Andersen, and A. N.
Andersen, “Risk of ovarian failure and fertility preserving
methods in girls and adolescents with a malignant disease,”
International Journal of Obstetrics and Gynaecology, vol. 117,
no. 2, pp. 163–174, 2010.
[38] I. Demeestere, P. Simon, Y. Englert, and A. Delbaere, “Pre-
liminaryexperienceofovariantissuecryopreservationproce-
dure: alternatives, perspectives and feasibility,” Reproductive
BioMedicine Online, vol. 7, no. 5, pp. 572–579, 2003.
[39] J. Donnez and S. Bassil, “Indications for cryopreservation of
ovariantissue,”HumanReproductionUpdate,vol.4,no .3,pp .
248–259, 1998.
[40] M. Sommezer and K. Oktay, “Fertility reservation in female
patients,” Human Reproduction Update,v o l .1 0 ,n o .3 ,p p .
251–266, 2004.
[41] J.Levine,A.Canada,andC.J.Stern,“Fertilitypreservationin
adolescents and young adults with cancer,” Journal of Clinical
Oncology, vol. 28, no. 32, pp. 4831–4841, 2010.
[42] J. Y. J. Huang, T. Tulandi, H. Holzer et al., “Cryopreservation
of ovarian tissue and in vitro matured oocytes in a female
with mosaic Turner syndrome: case report,” Human Repro-
duction, vol. 23, no. 2, pp. 336–339, 2008.
[43] B. Birgit, H. Julius, R. Carsten et al., “Fertility preservation in
girls with turner syndrome: prognostic signs of the presence
of ovarian follicles,” Journal of Clinical Endocrinology and
Metabolism, vol. 94, no. 1, pp. 74–80, 2009.
[44] M. von Wolﬀ, M. Montag, R. Dittrich, D. Denschlag,
F. Nawroth, and B. Lawrenz, “Fertility preservation in
women—a practical guide to preservation techniques and
therapeutic strategies in breast cancer, Hodgkin’s lymphoma
and borderline ovarian tumours by the fertility preservation
network FertiPROTEKT,” Archives of Gynecology and Obstet-
rics, vol. 284, no. 2, pp. 427–435, 2011.
[45] D. Meirow, S. J. Fasouliotis, D. Nugent, J. G. Schenker, R.
G. Gosden, and A. J. Rutherford, “A laparoscopic technique
for obtaining ovarian cortical biopsy specimens for fertility
conservation in patients with cancer,” Fertility and Sterility,
vol. 71, no. 5, pp. 948–951, 1999.
[ 4 6 ]C .Y .A n d e r s e n ,M .R o s e n d a h l ,A .G .B y s k o ve ta l . ,“ T w o
successful pregnancies following autotransplantation of
frozen/thawed ovarian tissue,” Human Reproduction, vol. 23,
no. 10, pp. 2266–2272, 2008.
[47] D. A. Gook, D. H. Edgar, and C. Stern, “Eﬀect of cooling
rate and dehydration regimen on the histological appearance
of human ovarian cortex following cryopreservation in 1,2-
propanediol,” Human Reproduction, vol. 14, no. 8, pp. 2061–
2068, 1999.
[48] V. Keros, S. Xella, K. Hultenby et al., “Vitriﬁcation versus
controlled-rate freezing in cryopreservation of human ovar-
ian tissue,” Human Reproduction, vol. 24, no. 7, pp. 1670–
1683, 2009.
[49] O. Oktem, E. Alper, B. Balaban et al., “Vitriﬁed human
ovaries have fewer primordial follicles and produce less
antim¨ ullerian hormone than slow-frozen ovaries,” Fertility
and Sterility, vol. 95, no. 8, pp. 2661.e1–2664.e1, 2011.
[50] M. A. Bedaiwy, M. R. Hussein, C. Biscotti, and T. Falcone,
“Cryopreservation of intact human ovary with its vascular
pedicle,” Human Reproduction, vol. 21, no. 12, pp. 3258–
3269, 2006.10 Obstetrics and Gynecology International
[51] A. Revel, A. Elami, A. Bor, S. Yavin, Y. Natan, and A. Arav,
“Whole sheep ovary cryopreservation and transplantation,”
Fertility and Sterility, vol. 82, no. 6, pp. 1714–1715, 2004.
[52] M. Sheikhi, K. Hultenby, B. Niklasson, M. Lundqvist, and
O. Hovatta, “Clinical grade vitriﬁcation of human ovarian
tissue: an ultrastructural analysis of follicles and stroma in
vitriﬁed tissue,” Human Reproduction, vol. 26, no. 3, pp. 594–
603, 2011.
[53] A. T. Grazul-Bilska, J. Banerjee, I. Yazici et al., “Morphology
and function of cryopreserved whole ovine ovaries after
heterotopic autotransplantation,” Reproductive Biology and
Endocrinology, vol. 6, p. 16, 2008.
[54] M.Imhof,H.Bergmeister,M.Lipovac,M.Rudas,G.Hofstet-
ter, and J. Huber, “Orthotopic microvascular reanastomosis
of whole cryopreserved ovine ovaries resulting in pregnancy
and live birth,” Fertility and Sterility, vol. 85, supplement 1,
pp. 1208–1215, 2006.
[55] B. Martinez-Madrid, A. Camboni, M. M. Dolmans, S.
Nottola, A. van Langendonckt, and J. Donnez, “Apoptosis
and ultrastructural assessment after cryopreservation of
whole human ovaries with their vascular pedicle,” Fertility
and Sterility, vol. 87, no. 5, pp. 1153–1165, 2007.
[56] J. Y. J. Huang, R. C. Chian, L. Gilbert et al., “Retrieval of
immature oocytes from unstimulated ovaries followed by in
vitro maturation and vitriﬁcation: a novel strategy of fertility
preservation for breast cancer patients,” American Journal of
Surgery, vol. 200, no. 1, pp. 177–183, 2010.
[57] S. G. Kristensen, A. Rasmussen, A. G. Byskov, and C. Y.
Andersen, “Isolation of pre-antral follicles from human
ovarian medulla tissue,” Human Reproduction, vol. 26, no. 1,
pp. 157–166, 2011.
[58] M.A.Bedaiwy,S.A.El-Nashar,A.M.elSamanetal.,“Repro-
ductive outcome after transplantation of ovarian tissue: a
systematic review,” Human Reproduction, vol. 23, no. 12, pp.
2709–2717, 2008.
[59] J. Donnez, S. Silber, C. Y. Andersen et al., “Children born
after autotransplantation of cryopreserved ovarian tissue. A
review of 13 live births,” Annals of Medicine, vol. 43, no. 6,
pp. 437–450, 2011.
[60] K. T. Schmidt, M. Rosendahl, E. Ernst et al., “Autotrans-
plantation of cryopreserved ovarian tissue in 12 women
with chemotherapy-induced premature ovarian failure: the
Danish experience,” Fertility and Sterility,v o l .9 5 ,n o .2 ,p p .
695–701, 2011.
[61] M.vonWolﬀ,J.Donnez,O.Hovattaetal.,“Cryopreservation
and autotransplantation of human ovarian tissue prior to
cytotoxic therapy—a technique in its infancy but already
successful in fertility preservation,” European Journal of
Cancer, vol. 45, no. 9, pp. 1547–1553, 2009.
[62] I. Demeestere, P. Simon, S. Emiliani, A. Delbaere, and Y.
Englert, “Orthotopic and heterotopic ovarian tissue trans-
plantation,” Human Reproduction Update,v o l .1 5 ,n o .6 ,p p .
649–665, 2009.
[63] K. Oktay, “Ovarian tissue cryopreservation and transplan-
tation: preliminary ﬁndings and implications for cancer
patients,”HumanReproductionUpdate,vol.7,no.6,pp.526–
534, 2001.
[64] I. Demeestere, P. Simon, F. Buxant et al., “Ovarian function
and spontaneous pregnancy after combined heterotopic and
orthotopic cryopreserved ovarian tissue transplantation in
a patient previously treated with bone marrow transplanta-
tion: case report,” Human Reproduction,v o l .2 1 ,n o .8 ,p p .
2010–2014, 2006.
[65] M. Rosendahl, A. Loft, A. G. Byskov et al., “Biochemical
pregnancy after fertilization of an oocyte aspirated from a
heterotopic autotransplant of cryopreserved ovarian tissue:
case report,” Human Reproduction, vol. 21, no. 8, pp. 2006–
2009, 2006.
[66] K.Oktay,C.G.Hilders,andJ.B.Trimbos,“Successfulhuman
ovarian autotransplantation to the upper arm,” Cancer, vol.
103, no. 9, pp. 1982–1983, 2005.
[67] A.Revel,N.Laufer,A.BenMeir,M.Lebovich,andE.Mitrani,
“Micro-organ ovarian transplantation enables pregnancy: a
case report,” Human Reproduction, vol. 26, no. 5, pp. 1097–
1103, 2011.
[68] M. M. Dolmans, W. Y. Yuan, A. Camboni et al., “Develop-
ment of antral follicles after xenografting of isolated small
human preantral follicles,” Reproductive BioMedicine Online,
vol. 16, no. 5, pp. 705–711, 2008.
[69] J. Smitz, M. M. Dolmans, J. Donnez et al., “Current
achievements and future research directions in ovarian tissue
culture, in vitro follicle development and transplantation:
implications for fertility preservation,” Human Reproduction
Update, vol. 16, no. 4, Article ID dmp056, pp. 395–414, 2010.
[70] R. Abir, B. Fisch, S. Jessel, C. Felz, A. Ben-Haroush, and R.
Orvieto, “Improving posttransplantation survival of human
ovarian tissue by treating the host and graft,” Fertility and
Sterility, vol. 95, no. 4, pp. 1205–1210, 2011.
[ 7 1 ]M .L e p o r r i e r ,P .v o nT h e o b a l d ,J .L .R o ﬀe, and G. Muller,
“A new thechnique to protect ovarian function before
pelvic irradiation. Heterotopic ovarian autotransplantation,”
Cancer, vol. 60, no. 9, pp. 2201–2204, 1987.
[ 7 2 ]M .L e p o r r i e r ,J .L .R o ﬀe, P. von Theobald, G. Muller, and
K. Oktay, “Autologous transplantation of whole ovaries vs
ovarian cortical strips,” Journal of the American Medical Asso-
ciation, vol. 287, no. 1, pp. 44–45, 2002.
[73] C.G.Hilders,A.G.Baranski,L.Peters,A.Ramkhelawan,and
J. B. Trimbos, “Successful human ovarian autotransplanta-
tion to the upper arm,” Cancer, vol. 101, no. 12, pp. 2771–
2778, 2004.
[74] S. J. Silber, G. Grudzinskas, and R. G. Gosden, “Successful
pregnancy after microsurgical transplantation of an intact
ovary,” The New England Journal of Medicine, vol. 359, no.
24, pp. 2617–2618, 2008.
[75] K. Oktay and M. S¨ onmezer, “Chemotherapy and amen-
orrhea: risks and treatment options,” Current Opinion in
Obstetrics and Gynecology, vol. 20, no. 4, pp. 408–415, 2008.
[76] P. B. Gupta, D. Proia, O. Cingoz et al., “Systemic stromal
eﬀects of estrogen promote the growth of estrogen receptor-
negative cancers,” Cancer Research, vol. 67, no. 5, pp. 2062–
2071, 2007.
[77] O. Oktem and K. Oktay, “Fertility preservation for breast
cancer patients,” Seminars in Reproductive Medicine, vol. 27,
no. 6, pp. 486–492, 2009.
[78] J. D. Yager and N. E. Davidson, “Estrogen carcinogenesis in
breastcancer,”TheNewEnglandJournalofMedicine,vol.354,
no. 3, pp. 270–282, 2006.
[79] P. B. Gupta and C. Kuperwasser, “Contributions of estrogen
to ER-negative breast tumor growth,” Journal of Steroid
BiochemistryandMolecularBiology,vol.102,no.1–5,pp.71–
78, 2006.
[80] S. R. Nayak and A. N. Wakim, “Random-start gonadotropin-
releasing hormone (GnRH) antagonist-treated cycles with
GnRH agonist trigger for fertility preservation,” Fertility and
Sterility, vol. 96, no. 1, pp. e51–e54, 2011.
[81] M. S¨ onmezer, I. T¨ urk¨ u o l u ,U .C o k u n ,a n dK .O k t a y ,
“Random-start controlled ovarian hyperstimulation forObstetrics and Gynecology International 11
emergency fertility preservation in letrozole cycles,” Fertility
and Sterility, vol. 95, no. 6, pp. 2125.e9–225.e11, 2011.
[82] G. Vajta, Ed., Vitriﬁcation in Assisted Reproduction A User‘s
Manual and Troubleshooting Guide,I n f o r m aU K ,L o n d o n ,
UK, 2007.
[83] K. Oktay, A. P. Cil, and H. Bang, “Eﬃciency of oocyte cry-
opreservation: a meta-analysis,” Fertility and Sterility, vol. 86,
no. 1, pp. 70–80, 2006.
[84] B. Ata, R. C. Chian, and S. L. Tan, “Cryopreservation of
oocytesandembryosforfertilitypreservationforfemalecan-
cer patients,” Best Practice and Research: Clinical Obstetrics
and Gynaecology, vol. 24, no. 1, pp. 101–112, 2010.
[85] B. Ata, E. Shalom-Paz, R. C. Chian, and S. L. Tan, “In vitro
maturation of oocytes as a strategy for fertility preservation,”
ClinicalObstetricsandGynecology,vol.53,no.4,pp.775–786,
2010.
[86] R. C. Chian, L. Gilbert, J. Y. J. Huang et al., “Live birth after
vitriﬁcationofinvitromaturedhumanoocytes,”Fertilityand
Sterility, vol. 91, no. 2, pp. 372–376, 2009.
[87] T. J. Kim, L. R. Laufer, and S. W. Hong, “Vitriﬁcation of
oocytes produces high pregnancy rates when carried out in
fertile women,” Fertility and Sterility, vol. 93, no. 2, pp. 467–
474, 2010.
[88] A. Cobo and C. Diaz, “Clinical application of oocyte vitriﬁ-
cation: a systematic review and meta-analysis of randomized
controlledtrials,”FertilityandSterility,vol.96,no.2,pp.277–
285, 2011.
[89] R. C. Chian, J. Y. J. Huang, L. Gilbert et al., “Obstetric out-
comes following vitriﬁcation of in vitro and in vivo matured
oocytes,” Fertility and Sterility, vol. 91, no. 6, pp. 2391–2398,
2009.
[90] N. Noyes, E. Porcu, and A. Borini, “Over 900 oocyte cry-
opreservation babies born with no apparent increase in
congenital anomalies,” Reproductive BioMedicine Online, vol.
18, no. 6, article 3971, pp. 769–776, 2009.
[91] H. E. G. Holzer and S. L. Tan, “Fertility preservation in
oncology,” Minerva Ginecologica, vol. 57, no. 1, pp. 99–109,
2005.
[92] G.D.Rao,R.C.Chian,W.S.Sonetal.,“Fertilitypreservation
in women undergoing cancer treatment,” The Lancet, vol.
363, no. 9423, pp. 1829–1830, 2004.
[93] W. Y. Son, J. T. Chung, R. C. Chian et al., “A 38 h interval
between hCG priming and oocyte retrieval increases in vivo
and in vitro oocyte maturation rate in programmed IVM
cycles,” Human Reproduction, vol. 23, no. 9, pp. 2010–2016,
2008.
[94] W. Y. Son, J. T. Chung, B. Herrero et al., “Selection of the
optimal day for oocyte retrieval based on the diameter of the
dominantfollicleinhCG-primedinvitromaturationcycles,”
Human Reproduction, vol. 23, no. 12, pp. 2680–2685, 2008.
[95] K. Oktay, E. Demirtas, W. Y. Son, K. Lostritto, R. C. Chian,
and S. L. Tan, “In vitro maturation of germinal vesicle
oocytes recovered after premature luteinizing hormone
surge: description of a novel approach to fertility preser-
vation,” Fertility and Sterility, vol. 89, no. 1, pp. 228.e19–
228.e22, 2008.
[96] E. Demirtas, S. E. Elizur, H. Holzer et al., “Immature oocyte
retrieval in the luteal phase to preserve fertility in cancer
patients,” Reproductive BioMedicine Online,v o l .1 7 ,n o .4 ,p p .
520–523, 2008.
[97] Y. X. Cao, Q. Xing, L. Li et al., “Comparison of survival and
embryonic development in human oocytes cryopreserved by
slow-freezing and vitriﬁcation,” Fertility and Sterility, vol. 92,
no. 4, pp. 1306–1311, 2009.
[98] V. S¨ oderstr¨ om-Anttila, S. M¨ akinen, T. Tuuri, and A. M.
Suikkari, “Favourable pregnancy results with insemination
of in vitro matured oocytes from unstimulated patients,”
Human Reproduction, vol. 20, no. 6, pp. 1534–1540, 2005.
[99] S. L. Reinblatt and W. Buckett, “In vitro maturation for
patients with polycystic ovary syndrome,” Seminars in Repro-
ductive Medicine, vol. 26, no. 1, pp. 121–126, 2008.
[100] W. M. Buckett, R. C. Chian, H. Holzer, N. Dean, R.
Usher, and S. L. Tan, “Obstetric outcomes and congenital
abnormalities after in vitro maturation, in vitro fertilization,
and intracytoplasmic sperm injection,” Obstetrics and Gyne-
cology, vol. 110, no. 4, pp. 885–891, 2007.
[101] X. Y. Zhang, B. Ata, W. Y. Son, W. M. Buckett, S. L. Tan, and
A. Ao, “Chromosome abnormality rates in human embryos
obtained from in-vitro maturation and IVF treatment
cycles,” Reproductive BioMedicine Online,v o l .2 1 ,n o .4 ,p p .
552–559, 2010.
[102] K. M. Ataya, K. C. Palmer, C. M. Blacker, K. S. Moghissi, and
S. H. Mohammad, “Inhibition of rat ovarian [3H]thymidine
uptake by luteinizing hormone-releasing hormone agonists:
a possible mechanism for preventing damage by cytotoxic
agents,”CancerResearch,vol.48,no.24,pp.7252–7256,1988.
[103] K. Ataya and K. Moghissi, “Chemotherapy-induced prema-
ture ovarian failure: mechanisms and prevention,” Steroids,
vol. 54, no. 6, pp. 607–626, 1989.
[104] K. Ataya, L. V. Rao, E. Lawrence, and R. Kimmel,
“Luteinizing hormone-releasing hormone agonist inhibits
cyclophosphamide-induced ovarian follicular depletion in
rhesus monkeys,” Biology of Reproduction,v o l .5 2 ,n o .2 ,p p .
365–372, 1995.
[105] L. Bokser, B. Szende, and A. V. Schally, “Protective eﬀects of
D-Trp6-luteinising hormone-releasing hormone microcap-
sules against cyclophosphamide-induced gonadotoxicity in
female rats,” British Journal of Cancer, vol. 61, no. 6, pp. 861–
865, 1990.
[106] M. A. Y¨ uce, P. B. Kaplan, F. G¨ ucer et al., “Prevention of
cyclophosphamide-induced ovarian damage by concomitant
administration of GnRHa in mice: a dose-dependent rela-
tionship?” European Journal of Gynaecological Oncology, vol.
25, no. 5, pp. 628–631, 2004.
[107] F. J. Montz, A. J. Wolﬀ, and J. C. Gambone, “Gonadal
protection and fecundity rates in cyclophosphamide-treated
rats,” Cancer Research, vol. 51, no. 8, pp. 2124–2126, 1991.
[108] D. Meirow, G. Assad, J. Dor, and J. Rabinovici, “The GnRh
antagonist cetrorelix reduces cyclophosphamide-induced
ovarian follicular destruction in mice,” Human Reproduction,
vol. 19, no. 6, pp. 1294–1299, 2004.
[109] D. R. Danforth, L. K. Arbogast, and C. I. Friedman,
“Acute depletion of murine primordial follicle reserve by
gonadotropin-releasing hormone antagonists,” Fertility and
Sterility, vol. 83, no. 5, pp. 1333–1338, 2005.
[110] C. N. C. D. Lemos, F. M. Reis, G. N. Pena, L. C. Silveira,
and A. F. Camargos, “Assessment of fertility protection and
ovarian reserve with GnRH antagonist in rats undergoing
chemotherapy with cyclophosphamide,” Reproductive Biol-
ogy and Endocrinology, vol. 8, p. 51, 2010.
[111] Z. Blumenfeld, I. Avivi, A. Eckman, R. Epelbaum, J. M.
Rowe, and E. J. Dann, “Gonadotropin-releasing hormone
agonistdecreaseschemotherapy-inducedgonadotoxicityand
premature ovarian failure in young female patients with
Hodgkin lymphoma,” Fertility and Sterility,v o l .8 9 ,n o .1 ,p p .
166–173, 2008.12 Obstetrics and Gynecology International
[112] Z. Blumenfeld and A. Eckman, “Preservation of fertility
and ovarian function and minimization of chemotherapy-
induced gonadotoxicity in young women by GnRH-a,” Jour-
nal of the National Cancer Institute. Monographs, no. 34, pp.
40–43, 2005.
[113] K. Oktay, M. S¨ onmezer, ¨ O. ¨ O k t e m ,K .F o x ,G .E m o n s ,a n dH .
Bang, “Absence of conclusive evidence for the safety and eﬃ-
cacyofgonadotropin-releasinghormoneanaloguetreatment
inprotectingagainstchemotherapy-inducedgonadalinjury,”
Oncologist, vol. 12, no. 9, pp. 1055–1066, 2007.
[114] R. Beck-Fruchter, A. Weiss, and E. Shalev, “GnRH agonist
therapy as ovarian protectants in female patients undergoing
chemotherapy: a review of the clinical data,” Human Repro-
duction Update, vol. 14, no. 6, pp. 553–561, 2008.
[115] J. H. Waxman, R. Ahmed, D. Smith et al., “Failure to pre-
serve fertility in patients with Hodgkin’s disease,” Cancer
Chemotherapy and Pharmacology, vol. 19, no. 2, pp. 159–162,
1987.
[116] A. Badawy, A. Elnashar, M. El-Ashry, and M. Shahat, “Gon-
adotropin-releasing hormone agonists for prevention of
chemotherapy-induced ovarian damage: prospective ran-
domized study,” Fertility and Sterility, vol. 91, no. 3, pp. 694–
697, 2009.
[117] K. Behringer, L. Wildt, H. Mueller et al., “No protection of
the ovarian follicle pool with the use of GnRH-analogues or
oral contraceptives in young women treated with escalated
BEACOPP for advanced-stage Hodgkin lymphoma. Final
results of a phase II trial from the German Hodgkin Study
Group,” Annals of Oncology, vol. 21, no. 10, pp. 2052–2060,
2010.
[118] B. Gerber, G. von Minckwitz, H. Stehle et al., “Eﬀect of
luteinizing hormone-releasing hormone agonist on ovarian
function after modern adjuvant breast cancer chemotherapy:
the GBG 37 ZORO study,” Journal of Clinical Oncology, vol.
29, no. 17, pp. 2334–2341, 2011.
[119] Z. Blumenfeld, “ZORO study: discrepancy between the
conclusion and the results,” Journal of Clinical Oncology, vol.
29, no. 24, p. 3340, 2011.
[120] M. A. Bedaiwy, A. M. Abou-Setta, N. Desai et al., “Gonadot-
ropin-releasing hormone analog cotreatment for preserva-
tion of ovarian function during gonadotoxic chemotherapy:
a systematic review and meta-analysis,” Fertility and Sterility,
vol. 95, no. 3, pp. 906.e4–914.e4, 2011.
[121] L. del Mastro, L. Boni, A. Michelotti et al., “Eﬀect of the
gonadotropin-releasinghormoneanaloguetriptorelinonthe
occurrence of chemotherapy-induced early menopause in
premenopausal women with breast cancer: a randomized
trial,” Journal of the American Medical Association, vol. 306,
no. 3, pp. 269–276, 2011.
[122] Y. Englert, P. Brice, F. Peccatori, D. T. Bron, and I.
Demeestere, “GnRH agonists, is there evidence for a protec-
tive eﬀect on the ovary?” Invited Lecture, World Congress on
Fertility Preservation, 2009.
[123] D. Meirow, J. Rabinovici, D. Katz, R. Or, Y. Shufaro, and D.
Ben-Yehuda, “Prevention of severe menorrhagia in oncol-
ogy patients with treatment-induced thrombocytopenia by
luteinizing hormone-releasing hormone agonist and depo-
medroxyprogesterone acetate,” Cancer, vol. 107, no. 7, pp.
1634–1641, 2006.
[124] Y. Morita, G. I. Perez, F. Paris et al., “Oocyte apoptosis is
suppressed by disruption of the acid sphingomyelinase gene
or by sphingosine-1-phosphate therapy,” Nature Medicine,
vol. 6, no. 10, pp. 1109–1114, 2000.
[125] F. Paris, G. I. Perez, Z. Fuks et al., “Sphingosine 1-phosphate
preserves fertility in irradiated female mice without propa-
gating genomic damage in oﬀspring,” Nature Medicine, vol.
8, no. 9, pp. 901–902, 2002.
[126] L. L. Kujjo, T. Laine, R. J. G. Pereira et al., “Enhancing
survival of mouse oocytes following chemotherapy or aging
by targeting bax and Rad51,” PLoS ONE, vol. 5, no. 2, Article
ID e9204, 2010.
[127] A. Carmely, D. Meirow, A. Peretz, M. Albeck, B. Bartoov,
and B. Sredni, “Protective eﬀect of the immunomodulator
AS101 against cyclophosphamide-induced testicular damage
in mice,” Human Reproduction, vol. 24, no. 6, pp. 1322–1329,
2009.
[128] T. K. Woodruﬀ, “Preserving fertility during cancer treat-
ment,” Nature Medicine, vol. 15, no. 10, pp. 1124–1125, 2009.